Cyclo Therapeutics Inc CYTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CYTH is a good fit for your portfolio.
News
-
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
-
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
-
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
-
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $1.12
- Day Range
- $1.12–1.15
- 52-Week Range
- $0.89–2.12
- Bid/Ask
- $1.12 / $1.28
- Market Cap
- $32.91 Mil
- Volume/Avg
- 12,290 / 32,437
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 21.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
Valuation
Metric
|
CYTH
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 53.95 |
Price/Sales | 21.16 |
Price/Cash Flow | — |
Price/Earnings
CYTH
Financial Strength
Metric
|
CYTH
|
---|---|
Quick Ratio | 0.47 |
Current Ratio | 1.01 |
Interest Coverage | — |
Quick Ratio
CYTH
Profitability
Metric
|
CYTH
|
---|---|
Return on Assets (Normalized) | −267.11% |
Return on Equity (Normalized) | −3,882.43% |
Return on Invested Capital (Normalized) | −2,190.61% |
Return on Assets
CYTH
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Zoetis Inc Class A
ZTS
| Pdnqhfcz | Jmjg | $82.1 Bil | |||
Merck KGaA ADR
MKKGY
| Hrhnmyhnfm | Qbyltqw | $75.2 Bil | |||
Haleon PLC ADR
HLN
| Sqmxfrzr | Dbkj | $41.4 Bil | |||
Viatris Inc
VTRS
| Vhpqdtwx | Gnwvf | $14.4 Bil | |||
Dr Reddy's Laboratories Ltd ADR
RDY
| Hxmztdfl | Vrvt | $13.7 Bil | |||
Catalent Inc
CTLT
| Jtwnzjb | Zlssyb | $10.6 Bil | |||
Perrigo Co PLC
PRGO
| Gqlmlvzqg | Gzy | $3.8 Bil | |||
Prestige Consumer Healthcare Inc
PBH
| Krjnlvdf | Bgsfj | $3.5 Bil | |||
Curaleaf Holdings Inc
CURLF
| Whyxbnpt | Xzsmx | $3.0 Bil | |||
Green Thumb Industries Inc
GTBIF
| Vgybfrldj | Zmjzz | $2.7 Bil |